The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
As Súil Pharma prepares for its next phase of testing and fundraising, the company’s focus remains clear: restore sight and transform lives. The journey from a Galway startup to an award-winning ...
Third Quarter 2025 Financial Highlights - Cash Position: Cash and cash equivalents were $81.3 million as of September 30, 2025, compared to $90.4 million as of June 30, 2025. - Revenue: ...
Kodiak Sciences Inc. , today reported recent business highlights and financial results for the third quarter ended September 30, 2025. "Kodiak Sciences has entered a period of strong, sustained ...
Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third ...
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ...
Chip maker Nvidia’s strong earnings and rock-solid guidance ease worries about an artificial-intelligence bubble.
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
Treatment with high dose aflibercept 8 mg can lead to similar visual outcomes with fewer injections for patients with RVO.
Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback